E. Saâda-Bouzid

R. Schiappa, G. Poissonnet, A. Bozec, 2020, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF).

J. Blay, B. Chauffert, F. Bertucci, 2017, European journal of cancer.

Synchronous primary neoplasia in patients with oropharyngeal cancer: Impact of tumor HPV status. A GETTEC multicentric study.

R. Schiappa, G. Poissonnet, A. Bozec, 2020, Oral oncology.

Prognostic value of HMGA2, CDK4, and JUN amplification in well-differentiated and dedifferentiated liposarcomas

B. Chetaille, J. Coindre, M. Péoc'h, 2015, Modern Pathology.

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.

J. Bourhis, C. Sire, A. Aupérin, 2021, The Lancet. Oncology.

Hyperprogression under Immune Checkpoint Inhibitor: a potential role for germinal immunogenetics

G. Milano, P. Brest, F. Peyrade, 2020, Scientific Reports.

Human papilloma virus integration sites and genomic signatures in head and neck squamous cell carcinoma

A. Nicolas, R. Rouzier, J. Klijanienko, 2022, Molecular oncology.

Microsatellite instability associated with durable complete response to PD-L1 inhibitor in head and neck squamous cell carcinoma.

A. Bozec, C. Badoual, K. Bénézery, 2018, Oral oncology.

Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

F. Bidault, A. Aupérin, E. Saâda-Bouzid, 2019, European journal of cancer.

Efficacy and safety of immune checkpoint inhibitors in elderly patients (≥70 years) with squamous cell carcinoma of the head and neck.

A. Aupérin, E. Saâda-Bouzid, É. Borcoman, 2019, Journal of Clinical Oncology.

NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial.

P. Ágoston, E. Wardelmann, V. Servois, 2019, The Lancet. Oncology.

Upfront surgery or definitive radiotherapy for patients with p16-negative oropharyngeal squamous cell carcinoma. A GETTEC multicentric study.

R. Schiappa, G. Poissonnet, A. Bozec, 2020, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Targeting of c-MET and AXL by cabozantinib is a potential therapeutic strategy for patients with head and neck cell carcinoma

A. Bozec, Yihai Cao, F. Luciano, 2022, Cell reports. Medicine.

Optimizing drug development in oncology by clinical trial simulation: Why and how?

Jocelyn Gal, Christophe Le Tourneau, Gérard Milano, 2017, Briefings Bioinform..

Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial.

J. Blay, F. Bertucci, O. Mir, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Germinal Immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitors

G. Milano, P. Brest, F. Peyrade, 2019, Investigational New Drugs.

Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

V. Servois, X. Paoletti, F. Peyrade, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Characteristics of very long responder to maintenance cetuximab after a platinum-cetuximab based chemotherapy for recurrent and/or metastatic head and neck squamous cell carcinomas (RM HNSCC).

A. Bozec, C. Lescure, F. Peyrade, 2017 .

Molecular genetics of head and neck squamous cell carcinoma

F. Peyrade, E. Saâda-Bouzid, J. Guigay, 2019, Current opinion in oncology.

A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial.

J. Machiels, I. Tinhofer, J. Canon, 2021, European journal of cancer.

LBA35 Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Randomized phase III GORTEC-REACH trial

C. Borel, J. Thariat, C. Sire, 2021, Annals of Oncology.

123MO Monalizumab, cetuximab and durvalumab in first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): A phase II trial

A. Pearson, F. Carrette, F. Rotolo, 2021, Annals of Oncology.

Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial.

J. Blay, G. Demetri, A. Tolcher, 2015, The Lancet. Oncology.

Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach.

J. Machiels, J. Bogaerts, I. Tinhofer, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Approach to the Patient with Recurrent/Metastatic Disease

F. Peyrade, E. Saâda-Bouzid, C. Michel, 2019, Current Treatment Options in Oncology.

A phase II study of monalizumab in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN): Results of the I1 cohort of the EORTC-HNCG-1559 trial (UPSTREAM)

J. Machiels, L. Dirix, J. Canon, 2019, Annals of Oncology.

Determinants of the access to remote specialised services provided by national sarcoma reference centres

J. Blay, F. Bertucci, P. Michelin, 2021, BMC cancer.

Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG)

F. Bertucci, A. Cesne, O. Mir, 2022, ESMO open.

A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic patients previously treated with both chemotherapy and pazopanib.

J. Blay, F. Bertucci, S. Salas, 2020, European journal of cancer.

Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.

J. Blay, F. Bertucci, S. Salas, 2016, The Lancet. Oncology.

Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)†

J. Blay, F. Bertucci, S. Salas, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial.

J. Blay, F. Bertucci, O. Mir, 2015, The Lancet. Oncology.

A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery

F. Bertucci, M. Toulmonde, A. Le Cesne, 2021, ESMO open.

High clinical benefit rates of pembrolizumab in very rare sarcoma histotypes: First results of the AcSé pembrolizumab study

F. Bertucci, S. Chevret, A. Cesne, 2019, Annals of Oncology.

Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis

S. Ogino, C. Luchini, N. Keum, 2019, Cancers.

Combination of monalizumab and cetuximab in recurrent or metastatic head and neck cancer patients previously treated with platinum-based chemotherapy and PD-(L)1 inhibitors.

A. Pearson, S. Salas, T. Seiwert, 2020 .

Surgical Margins and Adjuvant Therapies in Malignant Phyllodes Tumors of the Breast: A Multicenter Retrospective Study

J. Blay, F. Bertucci, S. Salas, 2020, Annals of Surgical Oncology.

Comparison of response evaluation criteria in solid tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: a retrospective analysis.

A. Italiano, S. Piperno-Neumann, N. Penel, 2015, European journal of cancer.

Rare bone sarcomas: A retrospective analysis of 145 adult patients from the French Sarcoma Group

J. Blay, F. Bertucci, M. Toulmonde, 2021, International journal of cancer.

Outcome of 449 adult patients with rhabdomyosarcoma: an observational ambispective nationwide study

J. Blay, O. Mir, M. Toulmonde, 2018, Cancer medicine.

Beyond EGFR Targeting in SCCHN: Angiogenesis, PI3K, and Other Molecular Targets

E. Saâda-Bouzid, C. le Tourneau, 2019, Front. Oncol..

Systemic treatment of metastatic squamous cell carcinoma of the head and neck: proposal for management changes.

C. Borel, F. Peyrade, E. Saâda-Bouzid, 2021, Current opinion in oncology.

MET immunolabelling is a useful predictive tool for MET gene amplification in glioblastoma

T. Virolle, D. Fontaine, F. Almairac, 2017, Neuropathology and applied neurobiology.

Methotrexate-Etoposide-Ifosfamide Compared with Doxorubicin-Cisplatin-Ifosfamide Chemotherapy in Osteosarcoma Treatment, Patients Aged 18-25 Years.

I. Ray-Coquard, S. Piperno-Neumann, P. Kerbrat, 2019, Journal of adolescent and young adult oncology.

526O High activity of nivolumab in patients with pathogenic exonucleasic domain POLE (edPOLE) mutated Mismatch Repair proficient (MMRp) advanced tumours

I. Bièche, S. Chevret, J. Grob, 2020 .

Targeting Harvey rat sarcoma viral oncogene homolog in head and neck cancer: how to move forward?

E. Saâda-Bouzid, Hédi Ben Yahia, F. Petit, 2023, Current opinion in oncology.

Chemotherapy postimmunotherapy for recurrent metastatic head and neck squamous cell carcinoma

M. Etienne-Grimaldi, E. Saâda-Bouzid, J. Guigay, 2023, Current opinion in oncology.

PD-1 blockade in solid tumors with defects in polymerase epsilon.

C. Tournigand, I. Bièche, M. Lamendola-Essel, 2022, Cancer discovery.

Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

J. Klijanienko, I. Bièche, M. Kamal, 2021, Investigational New Drugs.

Safety and efficacy of the anti-PD1 immunotherapy with nivolumab in trichoblastic carcinomas

S. Chevret, T. Jouary, L. Gambotti, 2023, Cancer immunology, immunotherapy : CII.

Enteral Nutrition during Radiotherapy for Oropharyngeal Cancers: Prevalence and Prognostic Factors Based on HPV Status (A GETTEC Study)

R. Schiappa, G. Poissonnet, A. Bozec, 2023, Journal of clinical medicine.

Hyperprogression under Immune Checkpoint Inhibitor: a potential role for germinal immunogenetics

G. Milano, P. Brest, F. Peyrade, 2020, Scientific Reports.

Tumor's flare-up and patterns of recurrence in patients (pts) with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) treated with anti-PD1/PD-L1 inhibitors.

V. Servois, X. Paoletti, J. Fayette, 2016 .

Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study.

J. Blay, F. Bertucci, O. Mir, 2021, European journal of cancer.

LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the gastric cancer cohort.

Juanita Lopez, H. Chung, A. Hendifar, 2021 .

Final safety and HRQoL results of the phase II/III Act.In.Sarc study with preoperative NBTXR3 plus radiotherapy versus radiotherapy in locally advanced soft-tissue sarcoma.

P. Ágoston, E. Wardelmann, V. Servois, 2022, International journal of radiation oncology, biology, physics.

High clinical activity of pembrolizumab in chordoma, alveolar soft part sarcoma (ASPS) and other rare sarcoma histotypes: The French AcSé pembrolizumab study from Unicancer.

J. Blay, F. Bertucci, S. Chevret, 2021 .

LBA41 LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours

Juanita Lopez, E. Castañón, M. Doherty, 2020 .

LBA58 Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REGO) in patients (pts) with relapsed advanced or metastatic chordoma, on behalf of the French Sarcoma Group (FSG) and Unicancer

J. Blay, F. Bertucci, O. Mir, 2021, Annals of Oncology.

LBA68 Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REG) in patients (pts) with metastatic relapsed Ewing sarcoma (ES), on behalf of the French Sarcoma Group (FSG) and UNICANCER

J. Blay, F. Bertucci, O. Mir, 2020 .

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors

E. Felip, B. Cho, Dae-Ho Lee, 2022, The oncologist.

TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

C. Sire, A. Aupérin, O. Capitain, 2019, Journal of Clinical Oncology.

Abstract PS12-07: Lenvatinib plus pembrolizumab for previously treated, advanced triple-negative breast cancer: Early results from the multicohort phase 2 LEAP-005 study

Juanita Lopez, S. Im, H. Chung, 2021 .

1619O High clinical benefit rates of single agent pembrolizumab in selected rare sarcoma histotypes: First results of the AcSé Pembrolizumab study

J. Blay, F. Bertucci, S. Chevret, 2020 .

LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the gastric cancer cohort.

Juanita Lopez, H. Chung, A. Hendifar, 2022, Journal of Clinical Oncology.

Results of a phase II study evaluating monalizumab in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).

S. Salas, T. Seiwert, R. Cohen, 2018, Annals of Oncology.

Epithelioid hemangio-endothelioma (EHE) in NETSARC: The nationwide series of 267 patients over 12 years.

F. Bertucci, M. Toulmonde, A. Italiano, 2023, European journal of cancer.

Regorafenib in patients with relapsed advanced or metastatic chordoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study

F. Bertucci, A. Italiano, A. Le Cesne, 2023, ESMO open.

18F-DOPA PET/CT in brain tumors: impact on multidisciplinary brain tumor board decisions

J. Darcourt, P. Bondiau, D. Fontaine, 2019, European Journal of Nuclear Medicine and Molecular Imaging.

Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach.

J. Machiels, J. Bogaerts, I. Tinhofer, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial.

J. Blay, F. Bertucci, O. Mir, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II study of preoperative afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of activity

S. Vacher, E. Girard, M. Kamal, 2023, Scientific reports.

Germinal Immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitors

G. Milano, P. Brest, F. Peyrade, 2019, Investigational New Drugs.

First-in-human clinical trial results with ABBV-184, a first-in-class T-cell Receptor/Anti-CD3 bispecific protein, in adults with Previously treated AML or NSCLC.

K. Freise, E. Saâda-Bouzid, M. Moskovitz, 2024, Expert review of anticancer therapy.

Efficacy of second-line chemotherapy or immune checkpoint inhibitors for patients with a prolonged objective response (≥ 6 months) after first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: a retrospective study

C. Borel, S. Richard, J. Fayette, 2023, BMC Cancer.

Efficacy and safety of immune checkpoint inhibitors in elderly patients (≥70 years) with squamous cell carcinoma of the head and neck.

A. Aupérin, E. Saâda-Bouzid, N. Basté, 2021, European journal of cancer.

Long term survival in adult osteosarcoma patients treated with a two-drug regimen: Final results of the OSAD93 phase II study of the FSG-GETO.

T. Valentin, D. Pérol, E. Bompas, 2024, European journal of cancer.

TPExtreme randomized trial: Quality of Life (QoL) and survival according to second-line treatments in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

J. Bourhis, C. Sire, A. Aupérin, 2020 .